Abeona Therapeutics Inc.
ABEOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 17, 2026 | Roth Capital | $17.00(+217%) | $5.37 | TheFly | |
| Aug 14, 2026 | Industrial Alliance Securities | $15.00(+154%) | $5.90 | TheFly | |
| Aug 14, 2026 | Oppenheimer | Jeff Jones | $21.00(+248%) | $6.04 | TheFly |
| Mar 17, 2026 | Stifel Nicolaus | Stephen Willey | $17.00(+257%) | $4.76 | StreetInsider |
| May 16, 2025 | Stifel Nicolaus | Stephen Willey | $20.00(+228%) | $6.10 | TheFly |
| Mar 5, 2025 | Oppenheimer | $16.00(+204%) | $5.26 | TheFly | |
| Nov 14, 2022 | Leerink Partners | $6.00(+45%) | $4.15 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Cantor Fitzgerald | maintain | Overweight | Sep 18, 2026 |
| Oppenheimer | maintain | Outperform | Aug 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2025 |
| Oppenheimer | maintain | Outperform | Aug 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 14, 2025 |
| Stifel | maintain | Buy | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 31, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Oct 29, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 12, 2024 |
| Cantor Fitzgerald | maintain | Overweight | May 16, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Apr 23, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Aug 24, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Jul 13, 2023 |
| SVB Leerink | maintain | Market Perform | Nov 14, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Nov 8, 2022 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.35 | $-0.23 | $11.4M | $12.2M |
| May 13, 2026 | $-0.30 | $-0.33 | $8.7M | $4.6M |
| Mar 17, 2026 | $-0.34 | $-0.35 | $5.4M | $4.4M |
| Nov 12, 2025 | $-0.10 | $-0.27 | — | $5.2M |
| Aug 11, 2025 | $1.71 | $-0.39 | $400.0K | $6.5M |
| May 14, 2025 | $-0.24 | $-0.35 | — | — |
| Mar 20, 2025 | $-0.24 | $-0.35 | — | $100.0K |
| Nov 14, 2024 | $-0.63 | $-0.38 | — | $100.0K |
News
CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a longer foundation-building period than a conventional drug because of the therapy's individualized manufacturing process, limited shelf life and specialized treatment-center requirements.
Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activation, an FDA approval for a drug the company licensed away and multiple fresh analyst ratings.
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified c…
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.